Prime-Boost Vaccination With BNT162b2 Induces High Neutralizing Activity Against SARS-CoV-2 Variants in Naïve and COVID-19-Convalescent Individuals. (24th September 2021)

• Record Type: Journal Article
• Authors: Luczkowiak, Joanna; Labiod, Nuria; Rivas, Gonzalo; Rolo, Marta; Lasala, Fátima; Lora-Tamayo, Jaime; Mancheno-Losa, Mikel; Rial, David; Pérez-Rivilla, Alfredo; Folgueira, María D; Delgado, Rafael
• Is Part Of: Open forum infectious diseases. Volume 8:Number 10(2021)
• Publication Date: 2021-09-24
• Subjects: SARS-CoV-2 -- COVID-19 -- neutralizing antibodies -- vaccines -- variants of concern; Communicable diseases -- Periodicals; Medical microbiology -- Periodicals; Infection -- Periodicals; 616.9
• DOI: 10.1093/ofid/ofab468
• Languages: English
• ISSNs: 2328-8957

Abstract

Abstract: Background: The objective of this study was to investigate the neutralizing response against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern (VoC) during coronavirus disease 2019 (COVID-19) convalescence and after vaccination. Methods: COVID-19-convalescent and -naïve individuals were tested for neutralizing activity against SARS-CoV-2 VoC Alpha, Beta, Gamma, and Delta at 1 and 7 months postinfection and 4–6 weeks after BNT162b2 vaccination. Results: Vaccination induced a high neutralizing response in naïve individuals. Interestingly, vaccination of convalescent patients induced a boosted response that was able to neutralize all VoC at high titers. Conclusions: Vaccination with BNT162b2 induced high levels of neutralization against SARS-CoV-2 VoC in most patients; this is especially beneficial in COVID-19-convalescent individuals.